中国实用外科杂志

中国实用外科杂志

• 专题笔谈 • 上一篇    下一篇

甲状腺微小癌术后促甲状腺激素抑制治疗认识和挑战

关海霞   

  1. 中国医科大学附属第一医院内分泌科 内分泌研究所，辽宁沈阳 110001
  • 出版日期:2016-05-01 发布日期:2016-04-28

  • Online:2016-05-01 Published:2016-04-28

摘要：

甲状腺微小癌（TMC）在分化型甲状腺癌中所占的比例明显增高。术后促甲状腺激素（TSH）抑制治疗对TMC病人仍然合理且必要。TMC并非均是低危癌，设定其TSH抑制治疗目标时，须遵循针对所有分化型甲状腺癌病人而推荐的风险评估策略，并依据对病情转归的动态随访评估结果进行调整。低危TMC应避免TSH过度抑制。

关键词: 甲状腺癌, 微小癌, 促甲状腺激素抑制治疗

Abstract:

Thyrotropin suppression therapy in thyroid microcarcinoma：Current understanding and challenges            GUAN Hai-xia. Department of Endocrinology and Metabolism，the First Affiliated Hospital of China Medical University，Shenyang 110001，China
Abstract    Thyroid microcarcinoma (TMC) has become an increasingly greater proportion of differentiated thyroid cancer. Postoperative thyrotropin（TSH）suppression therapy remains rational and necessary for patients with TMC. Not all TMCs harbor low risk, thus the target of TSH suppression therapy should be set according to dynamic risk evaluation. Aggressive TSH suppression should not be recommended in low-risk TMC.

Key words: thyroid cancer, microcarcinoma, thyrotropin suppression therapy